Go Pro
→ Your book attached (From Profits Run) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alector, Inc. stock logo
ALEC
Alector
$1.81
-2.7%		$2.04
$1.09
▼
$3.40
$207.68M0.621.31 million shs1.17 million shs
Eledon Pharmaceuticals, Inc. stock logo
ELDN
Eledon Pharmaceuticals
$2.49
+2.5%		$3.13
$1.35
▼
$4.60
$197.87M0.84808,417 shs963,796 shs
ImageneBio, Inc. stock logo
IMA
ImageneBio
$4.60
+0.4%		$5.25
$3.94
▼
$9.10
$51.99M0.7416,495 shs7,832 shs
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
$2.14
-2.3%		$3.18
$1.03
▼
$5.55
$182.66M1.371.36 million shs2.00 million shs
Don't Wait for the OpenAI IPO Cover
Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alector, Inc. stock logo
ALEC
Alector
-2.69%-7.18%-33.46%-12.14%-39.67%
Eledon Pharmaceuticals, Inc. stock logo
ELDN
Eledon Pharmaceuticals
+2.47%-6.04%-16.72%-36.96%-6.39%
ImageneBio, Inc. stock logo
IMA
ImageneBio
+0.44%-2.54%-7.26%-21.10%-45.95%
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
-2.28%-25.17%-42.93%-18.63%-2.28%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alector, Inc. stock logo
ALEC
Alector
$1.81
-2.7%		$2.04
$1.09
▼
$3.40
$207.68M0.621.31 million shs1.17 million shs
Eledon Pharmaceuticals, Inc. stock logo
ELDN
Eledon Pharmaceuticals
$2.49
+2.5%		$3.13
$1.35
▼
$4.60
$197.87M0.84808,417 shs963,796 shs
ImageneBio, Inc. stock logo
IMA
ImageneBio
$4.60
+0.4%		$5.25
$3.94
▼
$9.10
$51.99M0.7416,495 shs7,832 shs
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
$2.14
-2.3%		$3.18
$1.03
▼
$5.55
$182.66M1.371.36 million shs2.00 million shs
Don't Wait for the OpenAI IPO Cover
Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alector, Inc. stock logo
ALEC
Alector
-2.69%-7.18%-33.46%-12.14%-39.67%
Eledon Pharmaceuticals, Inc. stock logo
ELDN
Eledon Pharmaceuticals
+2.47%-6.04%-16.72%-36.96%-6.39%
ImageneBio, Inc. stock logo
IMA
ImageneBio
+0.44%-2.54%-7.26%-21.10%-45.95%
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
-2.28%-25.17%-42.93%-18.63%-2.28%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Alector, Inc. stock logo
ALEC
Alector
2.13
Hold$3.63100.28% Upside
Eledon Pharmaceuticals, Inc. stock logo
ELDN
Eledon Pharmaceuticals
2.33
Hold$10.00301.61% Upside
ImageneBio, Inc. stock logo
IMA
ImageneBio
2.25
Hold$29.00530.43% Upside
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
2.70
Moderate Buy$8.75308.88% Upside

Current Analyst Ratings Breakdown

Latest IMA, ELDN, ALEC, and PYXS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/25/2026
ImageneBio, Inc. stock logo
IMA
ImageneBio
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
9/25/2026
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
9/21/2026
Eledon Pharmaceuticals, Inc. stock logo
ELDN
Eledon Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
9/10/2026
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
Wedbush logo
Wedbush
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$6.00 ➝ $8.00
9/10/2026
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$7.00 ➝ $8.00
9/9/2026
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
Wells Fargo & Company logo
Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$12.00 ➝ $19.00
8/21/2026
ImageneBio, Inc. stock logo
IMA
ImageneBio
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$28.00
8/21/2026
ImageneBio, Inc. stock logo
IMA
ImageneBio
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$28.00
8/18/2026
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$7.00
8/13/2026
Alector, Inc. stock logo
ALEC
Alector
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
8/3/2026
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
Wells Fargo & Company logo
Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOverweight$12.00
(Data available from 10/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Alector, Inc. stock logo
ALEC
Alector
$21.05M9.60N/AN/A$0.28 per share6.46
Eledon Pharmaceuticals, Inc. stock logo
ELDN
Eledon Pharmaceuticals
N/AN/AN/AN/A$1.35 per shareN/A
ImageneBio, Inc. stock logo
IMA
ImageneBio
$800K65.26N/AN/A$11.91 per share0.39
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
$13.86M12.88N/AN/A$0.86 per share2.49
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Alector, Inc. stock logo
ALEC
Alector
-$142.93M-$1.10N/AN/AN/A-850.13%-531.03%-44.00%11/5/2026 (Estimated)
Eledon Pharmaceuticals, Inc. stock logo
ELDN
Eledon Pharmaceuticals
-$45.62M-$0.91N/AN/AN/AN/A-149.63%-50.84%11/13/2026 (Estimated)
ImageneBio, Inc. stock logo
IMA
ImageneBio
-$45.35M-$4.58N/AN/AN/AN/A-38.99%-34.84%N/A
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
-$79.62M-$1.41N/AN/AN/AN/A-215.23%-112.19%11/2/2026 (Estimated)

Latest IMA, ELDN, ALEC, and PYXS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2026Q2 2026
Eledon Pharmaceuticals, Inc. stock logo
ELDN
Eledon Pharmaceuticals
-$0.1580-$0.27-$0.1120-$0.27N/AN/A
8/13/2026Q2 2026
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
-$0.35-$0.40-$0.05-$0.40$0.03 millionN/A
8/6/2026Q2 2026
Alector, Inc. stock logo
ALEC
Alector
-$0.2286-$0.21+$0.0186-$0.21$1.71 million$3.32 million
8/5/2026Q2 2026
ImageneBio, Inc. stock logo
IMA
ImageneBio
-$0.90-$0.63+$0.27-$0.63N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Alector, Inc. stock logo
ALEC
Alector
N/AN/AN/AN/AN/A
Eledon Pharmaceuticals, Inc. stock logo
ELDN
Eledon Pharmaceuticals
N/AN/AN/AN/AN/A
ImageneBio, Inc. stock logo
IMA
ImageneBio
N/AN/AN/AN/AN/A
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Alector, Inc. stock logo
ALEC
Alector
0.80
5.26
5.26
Eledon Pharmaceuticals, Inc. stock logo
ELDN
Eledon Pharmaceuticals
N/A
7.90
7.90
ImageneBio, Inc. stock logo
IMA
ImageneBio
N/A
21.47
21.47
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
N/A
1.34
1.34

Institutional Ownership

CompanyInstitutional Ownership
Alector, Inc. stock logo
ALEC
Alector
85.83%
Eledon Pharmaceuticals, Inc. stock logo
ELDN
Eledon Pharmaceuticals
56.77%
ImageneBio, Inc. stock logo
IMA
ImageneBio
75.00%
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
39.07%

Insider Ownership

CompanyInsider Ownership
Alector, Inc. stock logo
ALEC
Alector
8.30%
Eledon Pharmaceuticals, Inc. stock logo
ELDN
Eledon Pharmaceuticals
9.60%
ImageneBio, Inc. stock logo
IMA
ImageneBio
2.22%
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
5.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
Alector, Inc. stock logo
ALEC
Alector
103111.66 million102.39 millionOptionable
Eledon Pharmaceuticals, Inc. stock logo
ELDN
Eledon Pharmaceuticals
3381.26 million73.46 millionOptionable
ImageneBio, Inc. stock logo
IMA
ImageneBio
1811.35 million11.10 millionNot Optionable
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
5683.41 million78.65 millionOptionable

Recent News About These Companies

Pyxis Oncology Closes $110 Million Public Offering to Advance MICVO Clinical Development
October 2 at 7:11 AM  |  quiverquant.comQ
Pyxis Oncology Announces Closing of Up to $282.6 Million Public Offering
October 2 at 7:00 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/02/3373740/0/en/pyxis-oncology-announces-closing-of-up-to-282-6-million-public-offering.html
Comparing Pyxis Oncology (NASDAQ:PYXS) & Inovio Pharmaceuticals (NASDAQ:INO)
October 1 at 4:15 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31073086
Pyxis Oncology prices public offering expected to raise ~$110 million
September 30 at 4:22 PM  |  thepharmaletter.comT
Pyxis Prices $110 Mln Offering, With Potential Proceeds Of $282 Mln To Advance Lead Cancer Drug
September 30 at 11:20 AM  |  rttnews.comhttps://www.rttnews.com/3695218/pyxis-prices-110-mln-offering-with-potential-proceeds-of-282-mln-to-advance-lead-cancer-drug.aspx
Biggest stock movers Wednesday: BA, PYXS, NOC, and more
September 30 at 6:19 AM  |  msn.comhttps://www.msn.com/en-us/news/other/biggest-stock-movers-wednesday-ba-pyxs-noc-and-more/ar-AA2dfJAB
Pyxis Oncology shares slide after pricing $110M registered public offering
September 30 at 6:19 AM  |  seekingalpha.comhttps://seekingalpha.com/news/4648328-pyxis-oncology-shares-slide-after-pricing-110m-registered-public-offering
Pyxis Oncology Announces Pricing of Up to $282.6 Million Public Offering
September 30 at 1:11 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/30/3371511/0/en/pyxis-oncology-announces-pricing-of-up-to-282-6-million-public-offering.html
Pyxis Oncology Announces Proposed Public Offering - September 29, 2026
September 29, 2026  |  biospace.comB
Pyxis Oncology terminates $150M ATM stock offering program
September 29, 2026  |  streetinsider.comhttps://www.streetinsider.com/Corporate+News/Pyxis+Oncology+terminates+%24150M+ATM+stock+offering+program/27122793.html
Acciones de Pyxis Oncology caen tras anuncio de oferta pública
September 29, 2026  |  es-us.finanzas.yahoo.comhttps://es-us.finanzas.yahoo.com/noticias/acciones-pyxis-oncology-caen-anuncio-211955600.html
Pyxis Oncology stock falls on public offering announcement
September 29, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/pyxis-oncology-stock-falls-public-211955345.html
Pyxis Oncology Announces Proposed Registered Public Offering of Common Stock, Pre-Funded Warrants and Common Warrants
September 29, 2026  |  quiverquant.comQ
Pyxis Oncology Announces Proposed Public Offering
September 29, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/29/3371341/0/en/pyxis-oncology-announces-proposed-public-offering.html
Analysts Have Conflicting Sentiments on These Healthcare Companies: Pyxis Oncology (PYXS), Moderna (MRNA) and Eli Lilly & Co (LLY)
September 23, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/LLY/pressreleases/4756577/analysts-have-conflicting-sentiments-on-these-healthcare-companies-pyxis-oncology-pyxs-moderna-mrna-and-eli-lilly-co-lly/
Reviewing Pyxis Oncology (NASDAQ:PYXS) and ProKidney (NASDAQ:PROK)
September 23, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31042222
Pyxis Oncology consensus price target increased by 16.92% to $8.61
September 15, 2026  |  msn.comhttps://www.msn.com/en-us/news/other/pyxis-oncology-consensus-price-target-increased-by-1692-to-861/ar-AA2cfryv
HC Wainwright Raises Earnings Estimates for Pyxis Oncology
September 14, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/estimates-hc-wainwright-raises-earnings-estimates-for-pyxis-oncology-2026-09-14/
Analysts Are Bullish on These Healthcare Stocks: AbbVie (ABBV), Pyxis Oncology (PYXS)
September 12, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/ABBV/pressreleases/4567408/analysts-are-bullish-on-these-healthcare-stocks-abbvie-abbv-pyxis-oncology-pyxs/
Pyxis Oncology: Setbacks Costing Nearly 2 Years Of Recovery
September 11, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4945598-pyxis-oncology-setbacks-costing-nearly-2-years-of-recovery
Pyxis Oncology (NASDAQ:PYXS) Price Target Raised to $8.00
September 10, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-pyxis-oncology-nasdaq-pyxs-price-target-raised-to-800-2026-09-10/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Broadcom logo displayed on a computer chip embedded in a circuit board with glowing blue connections.
The Path to $230 Billion: Broadcom Outlines the Next Phase of Its AI Growth Story
By Leo Miller | September 3, 2026
Adobe logo displayed on a wall behind an office desk with a laptop, notebook, and pens.
Analysts Are Punting Their Calls Into the Next Quarter After Adobe’s Mixed Earnings
By Dan Schmidt | September 14, 2026
Illustration of a server data center with an upward-trending chart line overlaid against a city skyline at sunset.
Q3 Earnings Could Be the Catalyst the Market Has Been Waiting For
By Thomas Hughes | September 8, 2026
Snowflake logo illuminated between server racks in a data center with a digital cloud graphic overhead.
Could Snowflake's Big Quarter Be a Sign of More to Come?
By Nathan Reiff | September 11, 2026
CrowdStrike logo, featuring a red falcon icon, displayed against a server data center corridor background.
The Ultimate Cyber Shield: CrowdStrike Rises Past $235
By Jeffrey Neal Johnson | September 16, 2026
Alector stock logo

Alector NASDAQ:ALEC

$1.81 -0.05 (-2.69%)
Closing price 10/2/2026 04:00 PM Eastern
Extended Trading
$1.82 +0.01 (+0.50%)
As of 10/2/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.

Eledon Pharmaceuticals stock logo

Eledon Pharmaceuticals NASDAQ:ELDN

$2.49 +0.06 (+2.47%)
Closing price 10/2/2026 04:00 PM Eastern
Extended Trading
$2.50 +0.01 (+0.40%)
As of 10/2/2026 07:31 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.

ImageneBio stock logo

ImageneBio NASDAQ:IMA

$4.60 +0.02 (+0.44%)
Closing price 10/2/2026 03:59 PM Eastern
Extended Trading
$4.61 +0.01 (+0.22%)
As of 10/2/2026 04:32 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

ImageneBio, Inc., a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California.

Pyxis Oncology stock logo

Pyxis Oncology NASDAQ:PYXS

$2.14 -0.05 (-2.28%)
Closing price 10/2/2026 04:00 PM Eastern
Extended Trading
$2.15 +0.01 (+0.28%)
As of 10/2/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients who previously progressed on PD-(L)1 inhibitors, which is in Phase 2 clinical trial for the treatment of solid tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and melanoma in combination with chemotherapy, radiation therapy, and immunotherapy. It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates directed to certain licensed targets, including PYX-201 and PYX-203, and products containing the ADC product candidates; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas